Table 1.
Clinical and immunological data for patients with septic shock.
| Septic shock patients (n = 30) | |
|---|---|
| Admission data | |
| Sex, male, n (%) | 21 (70) |
| Median age, years [IQR] | 66 [59–73] |
| Median BMI, kg/m2 [IQR] | 27 [21–34] |
| Median SAPS II [IQR] | 59 [48–77] |
| Median SOFA score (day 1) [IQR] | 8 [7–10] |
| Median plasma lactate level, mM [IQR] | 3.2 [2.6–5.2] |
| Median CCI [IQR] | 1.5 [0.1–3.3] |
| Comorbiditiesa, n (%) | |
| 0 | 10 (33.3) |
| ≥ 1 | 20 (66.7) |
| Primary site of infection, n (%) | |
| Abdominal | 9 (30) |
| UTI | 6 (20) |
| SST | 4 (13) |
| Others | 11 (37) |
| Type of primary infection, n (%) | |
| Community acquired | 13 (43) |
| Hospital acquired | 17 (57) |
| Documentation of infection, n (%) | |
| Gram-negative | 7 (23.3) |
| Gram-positive | 6 (20) |
| Virus | 1 (3.3) |
| Co-infection | 6 (20) |
| Non-documented infection | 10 (33.3) |
| Hydrocortisone, n (%) | 10 (33) |
| Day 3–4 data | |
| Immunology | |
| Median mHLA-DR, Ab/C [IQR] | 7348 [3838–10103] |
| Median TNFα secretion post-LPS stimulation, pg/mL [IQR] | 701 [320–1260] |
| Outcomes | |
| Vasopressor requirement, n (%) | 30 (100) |
| Median vasopressor duration, days [IQR] | 3.5 [2–6.8] |
| Hemofiltration, n (%) | 10 (33) |
| Mechanical ventilation, n (%) | 22 (73) |
| Median ICU length of stay, days [IQR] | 8 [4.2–12] |
| Median hospital length of stay, days [IQR] | 56 [20–78] |
| Mortality at day 28, n (%) | 4 (13.3) |
SAPS II was calculated after admission and SOFA score was measured after 24 h of ICU stay.
BMI body mass index, SAPS II simplified acute physiology score, SOFA sequential organ failure assessment, CCI Charlson comorbidity index, UTI urinary tract infection, SST skin and soft tissue, HLA-DR human leukocyte antigen DR, TNFα tumour necrosis factor alpha, LPS lipopolysaccharide, ICU intensive care unit.
aPresence of comorbidities was affirmative when at least one of the following comorbidity was present in the patient: chronic pulmonary disease, heart failure, myocardial infarction, ulcer, diabetes, renal failure, or malign solid tumour.